Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Letter Free access | 10.1172/JCI38981

Response to the letter by Eran et al.

Teiichi Furuichi and Tetsushi Sadakata

Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Wako, Japan.

Address correspondence to: Teiichi Furui­chi, Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako 351-0198, Japan. Phone: 81-48-467-5906; Fax: 81-48-467-6079; E-mail: tfuruichi@brain.riken.jp.

Find articles by Furuichi, T. in: PubMed | Google Scholar

Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Wako, Japan.

Address correspondence to: Teiichi Furui­chi, Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako 351-0198, Japan. Phone: 81-48-467-5906; Fax: 81-48-467-6079; E-mail: tfuruichi@brain.riken.jp.

Find articles by Sadakata, T. in: PubMed | Google Scholar

Published April 1, 2009 - More info

Published in Volume 119, Issue 4 on April 1, 2009
J Clin Invest. 2009;119(4):680–681. https://doi.org/10.1172/JCI38981.
© 2009 The American Society for Clinical Investigation
Published April 1, 2009 - Version history
View PDF

We read with great interest the comment by Eran et al. (1) regarding our recently published CADPS2 article in the JCI (2). We appreciate their comment that “exon 3 skipping likely represents a minor isoform rather than aberrant splicing” in the blood and postmortem cerebella of both healthy and autistic individuals. However, we are concerned about the sensitivity of detection of exon 3 skipping in their experiments and have a few replies to their letter.

First, the signal intensity of the exon 3–skipped CADPS2 band was considerably weaker than that of the normal band in some ASD and control blood samples (Figure 1A in ref. 1), in contrast to our results using samples from autism, but not pervasive development disorder — not otherwise specified (PDD-NOS), samples. Moreover, only a trace amount of skipped band was detected in all postmortem cerebella they analyzed (Figure 1D in ref. 1).

Second, they utilized RT-PCR with a nested amplification (at 70 cycles) to detect a control sample C14 with a skipped, but no normal, band (which was called “homozygous” in their comment; Figure 1C in ref. 1) and claimed that only one sample (control sample C14) was homozygous in their study. Little quantitative gain is generally noticed when increasing the number of cycles to such an extraordinary number. We are left wondering if only the skipped band would also be detected in case C14 using an ordinary RT-PCR method (similar to our method with 48 cycles), such as that used to generate the data shown in Figure 1A (1).

Third, their argument regarding one sample “homozygous for the exon 3–skipped allele” and “heterozygous” samples may not be appropriate, since the terms are usually used for genomic DNA, not mRNA. Also, it is yet unknown whether exon 3 skipping is of a cis- or trans-acting genetic origin or some other origin such as epigenetic.

Fourth, considering the results of Eran et al., we assume that a balance between exon 3–skipped and normal CADPS2 is important for the local secretion property (somato-dendritic, axonal, and synaptic secretion) of CADPS2. Our JCI article indicated that exon 3–skipped CADPS2 is not transported into the axons of cultured neurons and suggested that disturbance of this balance may cause a defect in local secretion. Impaired synaptic secretion should be more serious in neurons that dominantly express exon 3–skipped CADPS2 than in those that weakly express it. Thus, excessive exon 3 skipping, together with a combination of other genetic mutations, might contribute to susceptibility to autism.

Finally, we have recently succeeded in generating a mouse line expressing exon 3–skipped Cadps2 and have confirmed that exon 3 is critical for the subcellular localization of Cadps2 in neurons (our unpublished observations). Further studies will shed light on the association of exon 3 skipping with disturbed brain development and behavioral traits.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

J. Clin. Invest.119:680–681 (2009). doi:10.1172/JCI38981.

References
  1. Eran, A., et al. 2009. Comment on “Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients”. J. Clin. Invest. 119:679-680.
    View this article via: JCI Google Scholar
  2. Sadakata, T., et al. 2007. Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. J. Clin. Invest. 117:931-943.
    View this article via: JCI CrossRef PubMed Google Scholar
Version history
  • Version 1 (April 1, 2009): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts